NR4A1 and breast carcinoma: Our study also confirmed that hormone receptor-positive IDC patients have a significantly lower risk of breast cancer death than hormone receptor-negative patients, and hormone receptor-positive patients had a stable risk of breast cancer death over a 1–12 year period (0–1%).